Figure 1: DWDA prescription recipients and deaths*, by year, Oregon, 1998-2014



Similar documents
Oregon s Death with Dignity Act--2013

SAMPLE QUESTIONNAIRE

Hospice Care It s About How You Live

Selected Socio-Economic Data. Baker County, Florida

Community Information Book Update October Social and Demographic Characteristics

Selected Health Status Indicators DALLAS COUNTY. Jointly produced to assist those seeking to improve health care in rural Alabama

Group Benefits Evidence of Insurability for Comprehensive Optional Critical Illness Insurance

Illinois Standard Health Employee Application for Small Employers

Tae J Lee, MD, CMD, AGSF Medical Director Palliative Care and Hospice Vidant Medical Center

Alabama s Rural and Urban Counties

ALBANY PLASTIC SURGEONS, PLLC 4 Executive Park Drive Albany NY (518) PATIENT INFORMATION FORM

Blue Cross and Blue Shield of Illinois Cover Page to the Illinois Standard Health Employee Application for Small Employers

(928) MEDICAL HISTORY. Weight: _ Shoe size: _

Personal Injury Questionnaire

Diabetes: The Numbers

Illinois Standard Health Employee Application for Small Employers

Research and Statistics Note

Patient Registration Form

Illinois Standard Health Employee Application for Small Employers

End-of-Life Care: Diversity and Decisions Participant Handout

KIDNEY/PANCREAS REFERRAL PACKET Please attach the following information with each application.

Leading Causes of Death, by Race & Ethnicity

Physical and Mental Health Condition Prevalence and Comorbidity among Fee-for-Service Medicare- Medicaid Enrollees

PLEASE COMPLETE AND RETURN

Orthopaedic Institute of Ohio Demographic Information Date:

Welcome! Thank you for choosing our practice for your eye care needs! Please fill out our new patient registration paperwork.

CRIME VICTIM S REPARATION CLAIM FORM INSTRUCTIONS

Appendix C: Online Health Care Poll

End of Life Care in Dutch Nursing Homes: Dying with Dignity?

SASKATCHEWAN NNADAP TREATMENT SERVICES APPLICATION FORM Revised June, 2009 VAN LOONVCONSULTING

1. NAME 2. SOCIAL SECURITY NUMBER # 4. PRESENT OCCUPATION 5. PLANT 6. ADDRESS 8. TELEPHONE NUMBER 9. INTERVIEWER

Life Insurance Application Form

Chapter I Overview Chapter Contents

FEMALE DRIVER S LICENSE NUMBER STATE ISSUED PLACE OF BIRTH CITY STATE CITY STATE ZIP CITY STATE ZIP COUNTY USA

Referrals It is your responsibility to bring your referral if required. Failure to do so may result in cancellation of your appointment.

Medicare Advantage National Senior Survey 600 Senior Registered Voters in the Medicare Advantage Program February 24-28, 2015

Health Insurance Coverage: Estimates from the National Health Interview Survey, 2004

Application for Medicare Supplement Insurance Plan

Answers To Misconceptions About A Death with Dignity Law

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

OSHA INITIAL ASBESTOS MEDICAL QUESTIONNAIRE

Questionnaire: Use of placebo-medication for treating depression. 1. Explanation about the Placebo Treatment for Depression

2012 Georgia Diabetes Burden Report: An Overview

Medicare Supplement Application Aetna Life Insurance Company Aetna Administrator, P.O. Box 10374, Des Moines, IA 50306

Hospice Care. To Make a No Obligation No Cost Referral Contact our Admissions office at: Phone: Fax:

Final Questionnaire. Survey on Disparities in Quality of Health Care: Spring 2001

Dr. Ronnie Pollard, DPM 1563 Gilpin Street Denver, CO

Some life insurers make claims, we just pay them.

CALCAGNO AND ROSSI VEIN TREATMENT CENTER PATIENT INFORMATION SHEET. Last First Middle Name: Name: Initial: Male: Address: City: State: Zip:

Custodial Mothers and Fathers and Their Child Support: 2011

Patient Registration Form

Physician address. Physician phone

I have received a copy of the Notice of Privacy Practices True Health.

Frequently Asked Questions Regarding At Home and Inpatient Hospice Care

NATIONAL HEALTH FUND PRESENTATION

Globally 12% of all deaths among adults aged 30 years and over were attributed to tobacco.

Application for Individual Health Insurance

Health Care Access to Vulnerable Populations

Advanced Rehab Solutions 609 Morris Avenue Springfield, NJ 07081

Colonoscopy Data Collection Form

Generali Worldwide Group Health Insurance Enrolment and Health Insurance Applicant Form

How to Remove a Social History Smoke?

BARIATRIC SURGERY PROGRAM APPLICATION Updated: 6/22/2016 Page 1 of 9

Application for Medical Assistance for Families with Children

Total Cost of Cancer Care by Site of Service: Physician Office vs Outpatient Hospital

APPLICATION FOR UNDERGRADUATE STUDIES

LAST NAME FIRST NAME MI BIRTHDATE ADDRESS CITY STATE ZIP HOME PHONE# CELL# S.S. # ADDRESS

Indian River County BCC, Human Resources Department th Street, Vero Beach, Florida 32960

LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH:

Establishing an Advanced Illness Management (AIM) Model in a Community-Based Setting

TEXAS MEDICAL POWER OF ATTORNEY

Dallas Nursing Institute N. Abrams Rd, Suite 200, Dallas, TX 75243

Medicare- Medicaid Enrollee State Profile

HEALTH SCIENCE PROGRAMS Chipola College Marianna, Florida PARAMEDIC CERTIFICATE PROGRAM

Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System

Impact of Breast Cancer Genetic Testing on Insurance Issues

SOUTH PALM CARDIOVASCULAR ASSOCIATES, INC. CHARLES L. HARRING, M.D. NEW PATIENT INFORMATION FORM. Patient Name: Home Address:

Transcription:

Oregon s Death with Dignity Act--214 Oregon s Death with Dignity Act (DWDA), enacted in late 1997, allows terminally-ill adult Oregonians to obtain and use prescriptions from their physicians for self-administered, lethal doses of medications. The Oregon Public Health Division is required by the DWDA to collect compliance information and to issue an annual report. The key findings from 214 are presented below. The number of people for whom DWDA prescriptions were written (DWDA prescription recipients) and the resulting deaths from the ingestion of prescribed DWDA medications (DWDA deaths) reported in this summary are based on paperwork and death certificates received by the Oregon Public Health Division as of February 2, 21. For more detail, please view the figures and tables on our web site: http://www.healthoregon.org/dwd. Number 18 17 1 1 14 1 12 11 1 9 8 7 4 2 1 44 9 24 27 27 21 1 8 8 8 42 7 8 4 8 49 88 9 97 9 114 11 1998 1999 2 21 22 2 24 2 2 27 28 29 21 211 212 21 214 *Asof February 2, 21 Figure 1: DWDA prescription recipients and deaths*, by year, Oregon, 1998-214 DWDA prescription recipients DWDA deaths Year 71 8 121 7 1 1 As of February 2, 21, prescriptions for lethal medications were written for 1 people during 214 under the provisions of the DWDA, compared to 121 during 21 (Figure 1). At the time of this report, 1 people had died from ingesting the medications prescribed during 214 under DWDA. This corresponds to 1. DWDA deaths per 1, total deaths. 1 1 Rate per 1, deaths calculated using the total number of Oregon resident deaths in 21 (,91), the most recent year for which final death data are available. http://public.health.oregon.gov/providerpartnerresources/evaluationresearch/ DeathwithDignityAct/Documents/year17.pdf Page 1 of

Since the law was passed in 1997, a total of 1,27 people have had DWDA prescriptions written and 89 patients have died from ingesting medications prescribed under the DWDA. Of the 1 patients for whom DWDA prescriptions were written during 214, 94 (.%) ingested the medication; all 94 patients died from ingesting the medication. No patients that ingested the medication regained consciousness. Eleven patients with prescriptions written during the previous years (212 and 21) died after ingesting the medication during 214. Thirty-seven of the 1 patients who received DWDA prescriptions during 214 did not take the medications and subsequently died of other causes. Ingestion status is unknown for 24 patients who were prescribed DWDA medications in 214. For all of the 24 patients, both death and ingestion status are pending (Figure 2). Of the 1 DWDA deaths during 214, most (7.%) were aged years or older. The median age at death was 72 years. As in previous years, decedents were commonly white (9.2%) and welleducated (47.% had a least a baccalaureate degree). While most patients had cancer, the percent of patients with cancer in 214 (8.%) was lower than in previous years (79.4%), and the percent with amyotrophic lateral sclerosis (ALS) was higher (1.2% in 214, compared to 7.2% in previous years). While similar to previous years that most patients had cancer (8.%), this percent was lower than the average for previous years (79.4%); in contrast, the percent of patients with ALS was higher in 214 (1.2%) than in previous years (7.2%). Most (89.%) patients died at home, and most (9.%) were enrolled in hospice care either at the time the DWDA prescription was written or at the time of death. Excluding unknown cases, all (1.%) had some form of health care insurance, although the number of patients who had private insurance (9.8%) was lower in 214 than in previous years (2.9%). The number of patients who had only Medicare or Medicaid insurance was higher than in previous years (.2% compared to.%). As in previous years, the three most frequently mentioned end-of-life concerns were: loss of autonomy (91.4%), decreasing ability to participate in activities that made life enjoyable (8.7%), and loss of dignity (71.4%). Three of the 1 DWDA patients who died during 214 were referred for formal psychiatric or psychological evaluation. Prescribing physicians were present at the time of death for 14 patients (1.9%) during 214 compared to 1.9% in previous years. http://public.health.oregon.gov/providerpartnerresources/evaluationresearch/ DeathwithDignityAct/Documents/year17.pdf Page 2 of

A procedure revision was made in 21 to standardize reporting on the follow-up questionnaire. The new procedure accepts information about the time of death and circumstances surrounding death only when the physician or another health care provider was present at the time of death. Due to this change, data on time from ingestion to death is available for 2 of the 1 DWDA deaths during 214. Among those 2 patients, time from ingestion until death ranged from eleven minutes to one hour. Eighty-three physicians wrote 1 prescriptions during 214 (1-12 prescriptions per physician). During 214, no referrals were made to the Oregon Medical Board for failure to comply with DWDA requirements. Figure 2: Summary of DWDA prescriptions written and medications ingested in 214, as of February 2, 21 1 people had prescriptions written during 214 11 people with prescriptions written in previous years ingested medication during 214 94 ingested medication 7 did not ingest medication and subsequently died from other causes 24 ingestion and death status unknown 1 ingested medication 1 died from ingesting medication regained consciousness after ingesting medication; died of underlying illness http://public.health.oregon.gov/providerpartnerresources/evaluationresearch/ DeathwithDignityAct/Documents/year17.pdf Page of

Table 1. Characteristics and end of life care of 87 DWDA patients who have died from ingesting a lethal dose of medication as of February 2, 21, by year, Oregon, 1998 214 Characteristics Sex Male (%) Female (%) Age at death (years) 18 4 (%) 44 (%) 4 4 (%) 4 (%) 74 (%) 7 84 (%) 8+ (%) years (range) Race White (%) African American (%) American Indian (%) Asian (%) Pacific Islander (%) Other (%) Two or more races (%) Hispanic (%) Marital Status Married (%) 2 214 (N=1) 1998 21 (N=74) Total (N=89) N (%) 1 N (%) 1 N (%) 1 (.) 97 (2.7) 4 (2.7) 49 (4.7) 7 (47.) 4 (47.) 1 (1.) (.8) 7 (.8) 2 (1.9) 1 (2.1) 18 (2.1) (2.9) 8 (7.7) 1 (7.1) 28 (2.7) 1 (2.7) 184 (21.4) 29 (27.) 218 (28.9) 247 (28.8) 2 (21.9) 2 (27.) 229 (2.7) 19 (18.1) 94 (12.) 11 (1.2) 72 (29 9) 71 (2 9) 71 (2 9) 1 (9.2) 71 (97.) 81 (97.1) (.) 1 (.1) 1 (.1) (.) 2 (.) 2 (.2) 1 (1.) 8 (1.1) 9 (1.1) (.) 1 (.1) 1 (.1) 2 (1.9) 1 (.1) (.4) 1 (1.) 2 (.) (.4) 1 (1.) (.7) (.7) 48 (4.7) 47 (4.2) 9 (4.1) Widowed (%) 2 (24.8) 172 (22.9) 198 (2.1) Never married (%) (.7) (8.4) 9 (8.1) Divorced (%) 2 (2.8) 19 (22.) 194 (22.7) Education Less than high school (%) (.7) 4 (.) 1 (.) High school graduate (%) 2 (21.9) 14 (21.9) 187 (21.9) Some college (%) 2 (24.8) 198 (2.4) 224 (2.2) Baccalaureate or higher (%) (47.) 42 (4.7) 92 (4.9) Residence Metro counties (%) 4 (44.7) 1 (41.9) 1 (42.) Coastal counties (%) (.8) 7 (7.) (7.4) Other western counties (%) 4 (8.8) 2 (4.) (42.7) East of the Cascades (%) 11 (1.7) 4 (7.2) (7.) 2 End of life care Hospice Enrolled (%) 4 9 (9.) 4 (9.) 747 (9.) Not enrolled (%) 7 (7.) 7 (1.) 8 (9.7) Insurance 27 2 Private (%) 7 (9.8) 42 (2.9) 489 (.2) Medicare, Medicaid or Other Governmental (%) (.2) 2 (.) 11 (8.) None (%) (.) 12 (1.7) 12 (1.) 12 47 http://public.health.oregon.gov/providerpartnerresources/evaluationresearch/deathwithdignityact/documents/year17.pdf Page 4 of

Characteristics When medication was ingested 12 Prescribing physician Other provider, prescribing physician not present No provider At time of death 214 (N=1) 1998 21 (N=74) Total (N=89) Underlying illness Malignant neoplasms (%) 72 (8.) 9 (79.4) 8 (78.) Lung and bronchus (%) 1 (1.2) 19 (18.) 1 (18.1) Breast (%) 7 (.7) 7 (7.) 4 (7.) Colon (%) (4.8) 49 (.) 4 (.) Pancreas (%) 9 (8.) 47 (.) (.) Prostate (%) 2 (1.9) (4.4) (4.1) Ovary (%) (4.8) 28 (.7) (.9) Other (%) 28 (2.7) 24 (2.4) 271 (1.7) Amyotrophic lateral sclerosis (%) 17 (1.2) 4 (7.2) 71 (8.) Chronic lower respiratory disease (%) 4 (.8) 4 (4.) 8 (4.4) Heart Disease (%) (2.9) 14 (1.9) 17 (2.) HIV/AIDS (%) (.) 9 (1.2) 9 (1.1) Other illnesses (%) 9 (8.) 44 (.9) (.2) DWDA process Referred for psychiatric evaluation (%) (2.9) 44 (.9) 47 (.) Patient informed family of decision (%) 7 9 (9.) 4 (9.) 729 (9.2) Patient died at Home (patient, family or friend) (%) 94 (89.) 71 (9.) 81 (94.) Long term care, assisted living or foster care facility (%) 8 (7.) 29 (.9) 7 (4.) Hospital (%) (.) 1 (.1) 1 (.1) Other (%) (2.9) (.7) 8 (.9) Lethal medication Secobarbital (%) (.) 4 (.4) 4 (4.2) Pentobarbital (%) 41 (9.) 44 (4.) 8 (44.8) Other (%) 8 1 (1.) 7 (.9) 8 (.9) End of life concerns 9 Losing autonomy (%) Less able to engage in activities making life enjoyable (%) Loss of dignity (%) 1 Losing control of bodily functions (%) Burden on family, friends/caregivers (%) Inadequate pain control or concern about it (%) Financial implications of treatment (%) Health care provider present 11 (N=1) (N=74) (N=89) 9 (91.4) 8 (91.) 782 (91.) 91 (8.7) 7 (88.9) 78 (88.7) 7 (71.4) 4 (8.) 79 (79.) 2 (49.) 7 (.1) 428 (.1) 42 (4.) (4.) 42 (4.) (1.4) 178 (2.7) 211 (24.7) (4.8) 22 (2.9) 27 (.2) (N=1) Prescribing physician (%) 14 (1.9) 17 (1.9) 121 (1.7) Other provider, prescribing physician not present (%) (.9) 2 (9.2) 29 (4.8) No provider (%) 81 (8.2) 1 (44.9) 82 (49.) Complications 12 4 (N=1) 1 (N=74) 17 (N=89) Regurgitated 22 22 Seizures Other 1 1 None Other outcomes Regained consciousness after ingesting DWDA medications 1 14 4 81 2 8 (N=84) 119 28 7 21 487 244 (N=789) http://public.health.oregon.gov/providerpartnerresources/evaluationresearch/deathwithdignityact/documents/year17.pdf Page of 1 244 8 2 7 29

Characteristics Timing of DWDA event Duration (weeks) of patient physician relationship 14 Range Duration (days) between 1st request and death Range 11, 12 Minutes between ingestion and unconsciousness Range 11, 12 Minutes between ingestion and death Range (minutes hours) 214 (N=1) 1998 21 (N=74) Total (N=89) 19 12 1 1 112 19 19 1 72 87 2 2 4 48 47 1 49 1 19 1 19 1 74 89 2 1 2 8 1 8 1 8 487 7 27 2 27 2 2 11mins 1hr 1min 14hrs 1min 14hrs 2 492 12 8 22 47 1 2 4 7 8 9 1 11 12 1 14 s are excluded when calculating percentages. Includes Oregon Registered Domestic Partnerships. Clackamas, Multnomah, and Washington counties. Includes patients that were enrolled in hospice at the time the prescription was written or at time of death. Private insurance category includes those with private insurance alone or in combination with other insurance. Includes deaths due to benign and uncertain neoplasms, other respiratory diseases, diseases of the nervous system (including multiple sclerosis, Parkinson's disease and Huntington's disease), musculoskeletal and connective tissue diseases, cerebrovascular disease, other vascular diseases, diabetes mellitus, gastrointestinal diseases, and liver disease. First recorded beginning in 21. Since then, 7 patients (4.7%) have chosen not to inform their families, and 1 patients (2.%) have had no family to inform. There was one unknown case in 22, two in 2, one in 29, and in 21. Other includes combinations of secobarbital, pentobarbital, phenobarbital, and/or morphine. Affirmative answers only ("Don't know" included in negative answers). Categories are not mutually exclusive. Data unavailable for four patients in 21. First asked in 2. Data available for all 1 patients in 214, 2 patients between 1998 21, and 7 patients for all years. The data shown are for 21 214 since information about the presence of a health care provider/volunteer, in the absence of the prescribing physician, was first collected in 21. A procedure revision was made mid year in 21 to standardize reporting on the follow up questionnaire. The new procedure accepts information about time of death and circumstances surrounding death only when the physician or another health care provider is present at the time of death. This resulted in a larger number of unknowns beginning in 21. There have been a total of six patients who regained consciousness after ingesting prescribed lethal medications. These patients are not included in the total number of DWDA deaths. These deaths occurred in 2 (1 death), 21 (2 deaths), 211 (2 deaths) and 212 (1 death). Please refer to the appropriate years annual reports on our website (http://www.healthoregon.org/dwd) for more detail on these deaths. Previous reports listed 2 records missing the date care began with the attending physician. Further research with these cases has reduced the number of unknowns. http://public.health.oregon.gov/providerpartnerresources/evaluationresearch/deathwithdignityact/documents/year17.pdf Page of